Last reviewed · How we verify
Ticagrelor orodispersible tablets
Ticagrelor is a P2Y12 platelet receptor antagonist that reversibly inhibits ADP-induced platelet aggregation to prevent thrombotic events.
Ticagrelor is a P2Y12 platelet receptor antagonist that reversibly inhibits ADP-induced platelet aggregation to prevent thrombotic events. Used for Acute coronary syndrome (ACS) for prevention of thrombotic cardiovascular events, Secondary prevention of atherothrombotic events in patients with prior myocardial infarction.
At a glance
| Generic name | Ticagrelor orodispersible tablets |
|---|---|
| Sponsor | Azienda Ospedaliero Universitaria di Sassari |
| Drug class | P2Y12 receptor antagonist (antiplatelet agent) |
| Target | P2Y12 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Ticagrelor binds directly and reversibly to the P2Y12 adenosine diphosphate (ADP) receptor on platelet surfaces, blocking platelet activation and aggregation. This antiplatelet effect reduces the risk of stent thrombosis and cardiovascular events in acute coronary syndrome and other thrombotic conditions. The orodispersible tablet formulation allows rapid dissolution in the oral cavity for faster onset of action compared to standard tablets.
Approved indications
- Acute coronary syndrome (ACS) for prevention of thrombotic cardiovascular events
- Secondary prevention of atherothrombotic events in patients with prior myocardial infarction
Common side effects
- Bleeding (major and minor)
- Dyspnea (shortness of breath)
- Bradycardia
- Ventricular pauses
Key clinical trials
- The Impact of Aspirin Dose Modification on the Innate Immune Response - Will Lower Dose Aspirin Therapy Reduce the Response to Endotoxin (PHASE4)
- Ticagrelor Administered as Standard Tablet or Orodispersible Formulation (PHASE3)
- Study to Assess the Bioequivalence Between Ticagrelor Orodispersible Tablets and Ticagrelor Immediate-release Tablets in Japanese Subjects (PHASE1)
- Study to Assess the Bioavailability of Ticagrelor OD Tablet vs. IR Tablet (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: